Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Smart Eye in connection with a directed issue of new shares
Mandate

Vinge advises Smart Eye in connection with a directed issue of new shares

September 19, 2018 Capital Markets and Public M&A

Vinge has advised Smart Eye AB (publ) in connection with a directed issue of new shares to institutional investors as a result of which Swedbank Robur Ny Teknik will become a significant owner with 7.6% of the votes and capital.

The subscription price, i.e. SEK 52 per share, has been determined through a so called accelerated book building process. As a result of new share issue, Smart Eye has acquired approximately MSEK 114. Carnegie Investment Bank acted as financial adviser and sole book runner.

Vinge’s team primarily consisted of Anders Strid, Wibeke Sorling and company registration assistant Camilla Andersson.
 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026